2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the …

C Vrints, F Andreotti, KC Koskinas… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action

E Marijon, K Narayanan, K Smith, S Barra, C Basso… - The Lancet, 2023 - thelancet.com
Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD)
continues to be an enormous medical and societal challenge, claiming millions of lives …

Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches

S Heymans, NK Lakdawala, C Tschöpe, K Klingel - The Lancet, 2023 - thelancet.com
Dilated cardiomyopathy is conventionally defined as the presence of left ventricular or
biventricular dilatation or systolic dysfunction in the absence of abnormal loading conditions …

Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis

J Lehtonen, V Uusitalo, P Pöyhönen… - European heart …, 2023 - academic.oup.com
Cardiac sarcoidosis (CS) results from epithelioid cell granulomas infiltrating the myocardium
and predisposing to conduction disturbances, ventricular tachyarrhythmias, and heart …

Excessive Trabeculation of the Left Ventricle: JACC: Cardiovascular Imaging Expert Panel Paper

SE Petersen, B Jensen, N Aung, MG Friedrich… - Cardiovascular …, 2023 - jacc.org
Excessive trabeculation, often referred to as “noncompacted” myocardium, has been
described at all ages, from the fetus to the adult. Current evidence for myocardial …

[HTML][HTML] Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report

D Corrado, A Anastasakis, C Basso, B Bauce… - International Journal of …, 2024 - Elsevier
Arrhythmogenic cardiomyopathy (ACM) is a heart muscle disease characterized by
prominent “non-ischemic” myocardial scarring predisposing to ventricular electrical …

Management of cardiogenic shock: a narrative review

D Laghlam, S Benghanem, S Ortuno… - Annals of Intensive …, 2024 - Springer
Cardiogenic shock (CS) is characterized by low cardiac output and sustained tissue
hypoperfusion that may result in end-organ dysfunction and death. CS is associated with …

Electrically conductive collagen‐PEDOT: PSS hydrogel prevents post‐infarct cardiac arrhythmia and supports hiPSC‐cardiomyocyte function

K Roshanbinfar, M Schiffer, E Carls… - Advanced …, 2024 - Wiley Online Library
Myocardial infarction (MI) causes cell death, disrupts electrical activity, triggers arrhythmia,
and results in heart failure, whereby 50–60% of MI‐associated deaths manifest as sudden …